Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Amalgamation and shares

<< Previous

Bullboard Posts

Next >>

Comment by Forestviewon Apr 16, 2021 10:12am

203 Views

Post# 33010328

RE:RE:RE:Amalgamation and shares

So, if we are 75,000,000 shares after all is said and done, and the MC stays at $200M before it starts climbing, then our share price will be at $3.39.

Yikes.

But, I do wish they'd just rip off the bandaid and get this over with. This waiting game is excrutiating.

Doccole wrote:
The total float anticipated is around 75m. That's the number being tossed around here.

a billion dollar eval with that will put us at 13ish. I believe we will see that in the fall. The catalyst holding us back in a clear focus on total shares, and the potential the phase 3 gets pushed back due to covid. I imagine this will move once these questions are answered.

Hold tight!